CN100457100C - 甲氧氯普胺口腔崩解片及其生产方法 - Google Patents
甲氧氯普胺口腔崩解片及其生产方法 Download PDFInfo
- Publication number
- CN100457100C CN100457100C CNB2005101320900A CN200510132090A CN100457100C CN 100457100 C CN100457100 C CN 100457100C CN B2005101320900 A CNB2005101320900 A CN B2005101320900A CN 200510132090 A CN200510132090 A CN 200510132090A CN 100457100 C CN100457100 C CN 100457100C
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- metoclopramide
- microcrystalline cellulose
- cavity disintegration
- disintegration tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960004503 metoclopramide Drugs 0.000 title claims abstract description 28
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 210000000214 mouth Anatomy 0.000 title claims description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 238000004132 cross linking Methods 0.000 claims description 11
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 11
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 11
- 108010011485 Aspartame Proteins 0.000 claims description 10
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 10
- 229960003438 aspartame Drugs 0.000 claims description 10
- 235000010357 aspartame Nutrition 0.000 claims description 10
- 239000000605 aspartame Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 9
- 241000207199 Citrus Species 0.000 claims description 7
- 235000020971 citrus fruits Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 abstract description 7
- 101100273639 Carassius auratus ccna1 gene Proteins 0.000 abstract description 5
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 abstract 1
- 230000000994 depressogenic effect Effects 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 10
- 206010047700 Vomiting Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 3
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 2
- 229930195573 Amycin Natural products 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- -1 chemical compound metoclopramide chemical compound Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101320900A CN100457100C (zh) | 2005-12-23 | 2005-12-23 | 甲氧氯普胺口腔崩解片及其生产方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101320900A CN100457100C (zh) | 2005-12-23 | 2005-12-23 | 甲氧氯普胺口腔崩解片及其生产方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1823751A CN1823751A (zh) | 2006-08-30 |
CN100457100C true CN100457100C (zh) | 2009-02-04 |
Family
ID=36934696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101320900A Expired - Fee Related CN100457100C (zh) | 2005-12-23 | 2005-12-23 | 甲氧氯普胺口腔崩解片及其生产方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100457100C (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102871978B (zh) * | 2012-10-19 | 2014-04-09 | 河北仁合益康药业有限公司 | 一种左舒必利片及其制备方法 |
CN104606155A (zh) * | 2014-12-25 | 2015-05-13 | 海南卫康制药(潜山)有限公司 | 一种甲氧氯普胺组合物冻干片及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1257422A (zh) * | 1997-05-27 | 2000-06-21 | 武田药品工业株式会社 | 固体药物制剂 |
CN1429618A (zh) * | 2003-01-27 | 2003-07-16 | 清华大学 | 灯盏花口腔快速崩解片及其制备方法 |
CN1557414A (zh) * | 2004-01-18 | 2004-12-29 | 江西天施康科技开发有限公司 | 夏天无口腔崩解片及其制备方法 |
CN1559390A (zh) * | 2004-02-27 | 2005-01-05 | 中奇制药技术(石家庄)有限公司 | 对乙酰氨基酚口腔崩解片及其制备方法 |
CN1658838A (zh) * | 2002-06-10 | 2005-08-24 | 维塔科学有限公司 | 口腔崩解片及其制备方法 |
-
2005
- 2005-12-23 CN CNB2005101320900A patent/CN100457100C/zh not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1257422A (zh) * | 1997-05-27 | 2000-06-21 | 武田药品工业株式会社 | 固体药物制剂 |
CN1658838A (zh) * | 2002-06-10 | 2005-08-24 | 维塔科学有限公司 | 口腔崩解片及其制备方法 |
CN1429618A (zh) * | 2003-01-27 | 2003-07-16 | 清华大学 | 灯盏花口腔快速崩解片及其制备方法 |
CN1557414A (zh) * | 2004-01-18 | 2004-12-29 | 江西天施康科技开发有限公司 | 夏天无口腔崩解片及其制备方法 |
CN1559390A (zh) * | 2004-02-27 | 2005-01-05 | 中奇制药技术(石家庄)有限公司 | 对乙酰氨基酚口腔崩解片及其制备方法 |
Non-Patent Citations (2)
Title |
---|
新编药物学. 451-452,人民卫生出版社. 2004 |
新编药物学. 451-452,人民卫生出版社. 2004 * |
Also Published As
Publication number | Publication date |
---|---|
CN1823751A (zh) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6462827B2 (ja) | セルロース粉末 | |
US9616036B2 (en) | Sustained release dosage forms | |
JP4633469B2 (ja) | 経口固形医薬 | |
JP6383835B2 (ja) | セルロース粉末 | |
TW200808378A (en) | Solid preparation comprising enteric solid dispersion | |
JPWO2013180249A1 (ja) | セルロース粉末 | |
CN100457100C (zh) | 甲氧氯普胺口腔崩解片及其生产方法 | |
KR20110086741A (ko) | 직접 압축가능한 고 기능성 과립상 이염기성 인산칼슘 기재 공-가공된 부형제 | |
TWI513476B (zh) | 緩瀉劑 | |
CN109453131A (zh) | 一种铝碳酸镁咀嚼片及其制备工艺 | |
Singh et al. | Application of SeDeM expert system in formulation and development of fast disintegrating tablets using starch-glycine conjugates as superdisintegrant | |
CN101829044B (zh) | 一种他米巴罗汀固体制剂及其制备方法 | |
JP5644167B2 (ja) | 溶出改善されたケトチフェン又はその塩を含有する固形製剤 | |
CN110520110A (zh) | 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂 | |
Rajeswari et al. | Formulation and evaluation of Famotidine fast dissolving tablets using synthetic superdisintegrants | |
CN101804036B (zh) | 多潘立酮口腔崩解片及其制备方法 | |
Dev et al. | Preparation and evaluation of modified tamarind seed gum as a novel superdisintegrant | |
CN103705513B (zh) | 一种含有坎地沙坦酯和苯磺酸氨氯地平的药物组合物及其制备方法 | |
CN103893185B (zh) | 一种缬沙坦氢氯噻嗪分散片及其制备方法 | |
CN102204923B (zh) | 一种治疗骨质疏松症的药物组合物 | |
CN106880610A (zh) | 一种雷美替胺分散片及其制备方法 | |
CN107095852A (zh) | 白藜芦醇口腔崩解片 | |
CN105250232A (zh) | 一种伊卢多啉肠溶片及其制备方法 | |
CN114848646A (zh) | 包含取代的2-氨基吡啶衍生物的药物组合物及其制备方法 | |
CN104116719B (zh) | 一种石杉碱甲调释片组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 100083 Haidian District, Xueyuan Road, No. 30, A building, room No. 15, room, room 15 Patentee after: COSCI MED-TECH Co.,Ltd. Address before: 100080, room 1410, satellite building, No. 63, Zhichun Road, Beijing, Haidian District Patentee before: COSCI MED-TECH Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20191125 Address after: 1500008 3 / F, west side of building 13, Shuangtai Electric Power Industrial Park, No. 469, Xianfeng Road, Nangang District, Harbin City, Heilongjiang Province Patentee after: Harbin Kexin Bicheng Pharmaceutical Technology Development Co.,Ltd. Address before: 100083, Beijing, Xueyuan Road, Haidian District No. 30 Tiangong building, block A, room 15, room 15 Patentee before: COSCI MED-TECH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090204 |
|
CF01 | Termination of patent right due to non-payment of annual fee |